$AVTX News
Last published 1d ago
- 1d agoAVTXSTIFEL 2026 HEALTHCARE CONFERENCE - AVALO THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone. Thanks for joining us again. I'm Alex Thompson, biotech analyst here at Stiefel. Very happy to have Gary Neal, CEO of Avalo Therapeutics, for a fireside chat. Maybe to kick things off, Gary, if
- 2d agoAVTXAvalo Therapeutics, Inc. (AVTX) at Guggenheim 3rd Annual Healthcare Innovation Conference - AVALO THERAPEUTICS INCEarnings Call TranscriptsGood morning everyone, welcome to Guggenheim 3rd Annual Healthcare Innovation Conference. Our next presenting company is Avalo Therapeutics. Myself Yatin Suneja, one of the biotech analysts here, and it is my pleasure to
- 6d agoAVTXAvalo Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoAVTXAvalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewswireAdvancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward
- 1w agoAVTXAvalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated
- 1mo agoAVTXSTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - AVALO THERAPEUTICS INCEarnings Call TranscriptsHey, everybody, we're back. Very happy to have Gary Neal, CEO of Avalo Therapeutics with us for the next Fireside. I'll kick it over to Gary to give a brief overview of Abalo, and then we'll get into a Q&A. So with that,
- 2mo agoAVTXAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated
- 2mo agoAVTXAvalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated
- 3mo agoAVTXAvalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewswirePlans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody, with
- 3mo agoAVTXAvalo Therapeutics to Participate in the BTIG Biotechnology ConferenceGlobeNewswireWAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated
- 4mo agoAVTXAvalo Therapeutics to Participate in the Leerink Partners Therapeutics ForumGlobeNewswireWAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated
- 4mo agoAVTXAvalo Therapeutics to Join the Russell 2000® and Russell 3000® IndexesGlobeNewswireWAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated
- 4mo agoAVTXAvalo Therapeutics Appoints Ron Philip to Board of DirectorsGlobeNewswireWAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated
- 4mo agoAVTXAvalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β AntibodyGlobeNewswireIND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing
- 5mo agoAVTXAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 6mo agoAVTXAvalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewswireAchieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 programCompleted public offering of equity
- 6mo agoAVTXAvalo Therapeutics Announces Pricing of $375 Million Public OfferingGlobeNewswireWAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated
- 6mo agoAVTXAvalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireWAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated
- 6mo agoAVTXAvalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis SuppurativaGlobeNewswireSuccessfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the highest rates observed in
- 6mo agoAVTXAvalo Therapeutics Purchases Optional Milestone BuyoutGlobeNewswireWAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated
- 7mo agoAVTXAvalo Therapeutics Reports 2025 Financial Results and Recent Business UpdatesGlobeNewswireTopline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026Cash, cash equivalents and short-term investments of approximately $98
- 8mo agoAVTXAvalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 8mo agoAVTXAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 9mo agoAVTXAvalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 11mo agoAVTXAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 1y agoAVTXAvalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business UpdatesGlobeNewswireCompleted enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key
- 1y agoAVTXAvalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 1y agoAVTXAvalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaGlobeNewswireWAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 1y agoAVTXAvalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human ResourcesGlobeNewswireWAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 1y agoAVTXAvalo Therapeutics Appoints Kevin R. Lind to Board of DirectorsGlobeNewswireWAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 1y agoAVTXAvalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory
- 1y agoAVTXAvalo Reports Second Quarter 2025 Financial Results and Recent Business UpdatesGlobeNewswireTopline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113
- 1y agoAVTXAvalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of DirectorsGlobeNewswireWAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita
- 1y agoAVTXAvalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that
- 1y agoAVTXAvalo Reports First Quarter 2025 Financial Results and Recent Business UpdatesGlobeNewswireMike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March
- 1y agoAVTXAvalo Therapeutics to Participate in The Citizens Life Sciences ConferenceGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that
- 1y agoAVTXBHVNCOLLTRVIAvalo Therapeutics Appoints Michael Heffernan as Chairman of the BoardGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the
- 1y agoAVTXAvalo Reports 2024 Financial Results and Recent Business UpdatesGlobeNewswireTopline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of
- 1y agoAVTXAvalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that
- 1y agoAVTXAvalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that
- 1y agoAVTXAvalo Therapeutics Appoints Jennifer Riley as Chief Strategy OfficerGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the
- 1y agoAVTXAvalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement WarrantsGlobeNewswireProceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at least 2027 WAYNE, Pa.
- 2y agoAVTXAvalo Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that
- 2y agoAVTXAvalo Reports Third Quarter 2024 Financial Results and Recent Business UpdatesGlobeNewswireDosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of September 30, 2024 with
- 2y agoATNMRDHLAVTXTENXActinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of DirectorsPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs)...
- 2y agoAVTXAvalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaGlobeNewswireGlobal study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placeboTopline data expected in 2026 WAYNE, Pa. and ROCKVILLE,
- 2y agoAVTXDRRXHALOMESO+1KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial OfficerBusiness WireKaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO).
- 2y agoAVTXAvalo Announces Participation in September Investor ConferencesGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two
- 2y agoAVTXAvalo Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswireExpects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal OfficerCash on
- 2y agoAVTXAvalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical OfficerGlobeNewswireWAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. "We are thrilled